Speaking to reporters on January 4, Ella seemingly also took a back-swipe at Serum Institute of India (SII) chief Adar Poonawallas jibe calling vaccines other than those by AstraZeneca, Moderna and Pfizer as like water.
We do 200 percent honest clinical trials and yet we receive backlash. If I am wrong, tell me. Some companies have branded me like water," he said. Bharat Biotech was the first to identify the Zika virus and the first to file global patents for the Zika and Chikungunya vaccines, Ella said while emphasising their coronavirus vaccine was not inferior to the one developed by Pfizer.
Bharat Biotech has faced a barrage of questions and concerns after the Drugs Controller General of India (DCGI) announced the grant of emergency use authorisation for its Covaxin and AstraZeneca-Oxford Universitys vaccine candidate Covishield. SII is producing AstraZeneca's vaccine in India as Covishield.
An Indo-American News website. It covers Gossips, Politics, Movies, Technolgy, and Sports News and Photo Galleries and Live Coverage of Events via Youtube. The website is established in 2015 and is owned by AGK FIRE INC.
You can enroll as a voter for MLC elections now if you have not enrolled earlier. https://ceotserms1.telangana.gov.in/MLC/Form18.aspx : vs ||Vaccine War: Bharat Biotech vs Serum Institute Bharat Biotech Chairman Krishna Ella has hit back at doubters saying the company is receiving unfounded backlash as it has done 200 percent honest clinical trials for Covaxin, its candidate vaccine against COVID-19. Speaking to reporters on January 4, Ella seemingly also took a back-swipe at Serum Institute of India (SII) chief Adar Poonawallas jibe calling vaccines other than those by AstraZeneca, Moderna and Pfizer as like water. We do 200 percent honest clinical trials and yet we receive backlash. If I am wrong, tell me. Some companies have branded me like water," he said. Bharat Biotech was the first to identify the Zika virus and the first to file global patents for the Zika and Chikungunya vaccines, Ella said while emphasising their coronavirus vaccine was not inferior to the one developed by Pfizer. Bharat Biotech has faced a barrage of questions and concerns after the Drugs Controller General of India (DCGI) announced the grant of emergency use authorisation for its Covaxin and AstraZeneca-Oxford Universitys vaccine candidate Covishield. SII is producing AstraZeneca's vaccine in India as Covishield.
This website uses cookies.
